Provided by Tiger Trade Technology Pte. Ltd.

Qudian Inc.

3.83
0.0000
Volume:- -
Turnover:1.46M
Market Cap:632.43M
PE:5.75
High:3.83
Open:3.83
Low:3.83
Close:3.83
52wk High:5.08
52wk Low:2.04
Shares:165.13M
Float Shares:96.72M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.6661
EPS(LYR):0.0687
ROE:6.88%
ROA:-1.71%
PB:0.36
PE(LYR):55.73

Loading ...

Qudian Inc. Reports Third Quarter 2025 Unaudited Financial Results

THOMSON REUTERS
·
Nov 24, 2025

First Batch of "Parenting Subsidies" on the Way! 192,100 Changsha Residents to Receive Payments

Deep News
·
Nov 20, 2025

QD Laser, Inc. Reports Growth and Strategic Investments in Q2 FY2025

TIPRANKS
·
Nov 18, 2025

QD Laser Sees Parent FY Loss Y445.00M

Dow Jones
·
Nov 13, 2025

Stock Track | Qudian Inc. Stock Soars 5.14% Following Announcement of Name and Ticker Symbol Change

Stock Track
·
Nov 13, 2025

Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update

GlobeNewswire
·
Nov 12, 2025

Qudian Inc. Shareholders to Vote on Company Name and Ticker Symbol Change at Upcoming EGM

Reuters
·
Nov 12, 2025

Qudian board approves name change to High Templar Tech, symbol change

TIPRANKS
·
Nov 12, 2025

Qudian Inc - to Change Name to High Templar Tech Limited

THOMSON REUTERS
·
Nov 12, 2025

Qudian Inc. Announces Board Approval of Changes to Company Name and Ticker Symbol, as Well as Calling of Extraordinary General Meeting

THOMSON REUTERS
·
Nov 12, 2025

Qudian Inc - to Change Ticker Symbol to Htt

THOMSON REUTERS
·
Nov 12, 2025

AOC Launches New 24-inch Monitor at 649 Yuan: FHD 260Hz Screen with QD Quantum Dot Technology

Deep News
·
Nov 04, 2025

Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia

GlobeNewswire
·
Oct 22, 2025

2025 OCP Global Summit: Supernodes and "Scale Up" Take Center Stage

Deep News
·
Oct 22, 2025

Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis

GlobeNewswire
·
Oct 08, 2025

Why Is Arcus Biosciences Stock Trading Higher On Monday?

Benzinga_recent_news
·
Oct 07, 2025

LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative Symptoms

GlobeNewswire
·
Oct 06, 2025

Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension

GlobeNewswire
·
Sep 30, 2025

BRIEF-Qudian Announces Changes To Board Of Directors

Reuters
·
Sep 24, 2025

Qudian Inc. Announces Board of Directors Resignation as Mr. Yingming Li Steps Down

Reuters
·
Sep 24, 2025